Palisade Bio (NASDAQ:PALI) was advised by the European Patent Office that it will receive a patent for its lead investigational drug product, LB1148. The patent will publish on Dec. 22, 2021, and provide protection until 2035.
“With the European patent grant, this greatly strengthens the IP protection of our lead drug candidate, LB1148, for the global pharmaceutical market,” Thomas Hallam, Ph.D. and CEO of Palisade, said in a statement.
LB1148, which is advancing towards a Phase 3 program, is a protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.
Palisade already has received patents for LB1148 in the U.S., China, Australia, Japan, India, Mexico, and Taiwan “We are continuing to strengthen patent protections for LB1148 and its uses across the globe as we advance our clinical studies with LB1148,” Dr. Hallam added.